Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this registry is to evaluate the indication for EndoVenous Laser Ablation (EVLA) therapy. Can this be enhanced? What are the reasons for not using the laser? Therefore, this study aims to define clear indications for EVLA by registering the incentives of the participating investigators to use the laser instead of conventional corrective surgery for the treatment of varicose veins, at baseline and post-operative. Additionally, the efficacy and safety of the different varicose vein treatments will be evaluated by registering procedural characteristics, anatomic outcome (duplex ultrasound), quality of life (AVVQ) and postoperative pain (VAS).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with varicose veins | Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation | Device | Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm |
| Measure | Description | Time Frame |
|---|---|---|
| To define clear indications for EndoVenous Laser Ablation (EVLA) treatment of varicose veins. | The participating investigators will register the incentives (based on clinical examination and/or anatomic outcome by duplex ultrasound, as well as secondary considerations) to use laser ablation or conventional treatment for varicose veins in the study database in order to define clear indications for EndoVenous Laser Ablation (EVLA) treatment of varicose veins and to investigate whether the use of EVLA can be enlarged. | At baseline |
| To define clear indications for EndoVenous Laser Ablation (EVLA) treatment of varicose veins. | The participating investigators will re-evaluate the chosen treatment option and document this re-evaluation in the study database in order to define clear indications for EndoVenous Laser Ablation (EVLA) treatment of varicose veins and to investigate whether the use of EVLA can be enlarged. | At 6 weeks follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Procedural characteristics | Type of anesthesia | At index-procedure |
| Procedural characteristics | Number, type and length of veins treated |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
500 patients with varicose veins, indicative for treatment with Endovenous laser ablation (EVLA) or Surgery (ligation/stripping) according to routine patient care.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ziekenhuis Oost-Limburg (Sint-Jan,Genk; Sint-Barbara,Lanaken; ZMK,Maaseik) | Genk | Limburg | 3600 | Belgium |
Not provided
| ID | Term |
|---|---|
| D014648 | Varicose Veins |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| At index-procedure |
| Procedural characteristics | Total energy per patient and fiber (when using the ELVeS® Radial® 2ring slim fiber) | At index-procedure |
| Procedural characteristics | Number of procedures showing technical success, defined as the ability to treat the varicose veins as planned | At index-procedure |
| Procedural characteristics | Peri-operative adverse events (bleeding, incomplete treatment, technical defects, difficult visualization, …) | At index-procedure |
| Procedural characteristics | Duration of the index-procedure | At index-procedure |
| Pain scoring using the Visual Analog Scale (VAS) | The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain. The patient is asked to select the number on the scale that corresponds to the worst level of pain he/she experiences. Pain is classified into mild (1 - 30 mm), moderate (31 - 60 mm) and severe (61 - 100 mm). Absence of pain is defined as VAS = 0. | At discharge, up to 1 week |
| Pain scoring using the Visual Analog Scale (VAS) | The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain. The patient is asked to select the number on the scale that corresponds to the worst level of pain he/she experiences. Pain is classified into mild (1 - 30 mm), moderate (31 - 60 mm) and severe (61 - 100 mm). Absence of pain is defined as VAS = 0. | At 6 weeks follow-up |
| Anatomic success of EndoVenous Laser Ablation (EVLA) | Defined as occlusion of the treated veins and lack of reflux objectified with duplex ultrasonography. | At 6 weeks follow-up |
| Quality of life by scoring Aberdeen Varicose Vein Questionnaire (AVVQ) | Aberdeen Varicose Vein Questionnaire (AVVQ) is a validated tool for assessing the perceived health of patients with varicose veins. The AVVQ comprises 13 quality of life questions, including a set of manikin legs, on which participants are asked to draw their veins. | At baseline |
| Quality of life by scoring Aberdeen Varicose Vein Questionnaire (AVVQ) | Aberdeen Varicose Vein Questionnaire (AVVQ) is a validated tool for assessing the perceived health of patients with varicose veins. The AVVQ comprises 13 quality of life questions, including a set of manikin legs, on which participants are asked to draw their veins. | At 6 weeks follow-up |
| Quality of life by scoring Aberdeen Varicose Vein Questionnaire (AVVQ) | Aberdeen Varicose Vein Questionnaire (AVVQ) is a validated tool for assessing the perceived health of patients with varicose veins. The AVVQ comprises 13 quality of life questions, including a set of manikin legs, on which participants are asked to draw their veins. | At 6 months follow-up |
| Post-operative adverse events | Number of participants with numbness, persistent bruising, skin loss or ulceration, hematoma, infection, bleeding, deep venous thrombosis, etc. | At discharge, up to 1 week |
| Post-operative adverse events | Number of participants with numbness, persistent bruising, skin loss or ulceration, hematoma, infection, bleeding, deep venous thrombosis, etc. | At 6 weeks follow-up |
| Post-operative adverse events | Number of participants with numbness, persistent bruising, skin loss or ulceration, hematoma, infection, bleeding, deep venous thrombosis, etc. | At 6 months follow-up |
| Re-interventions | Number of participants with re-interventions | At discharge, up to 1 week |
| Re-interventions | Number of participants with re-interventions | At 6 weeks follow-up |
| Re-interventions | Number of participants with re-interventions | At 6 months follow-up |